Y Intercept Hong Kong Ltd Invests $8.41 Million in Tempus AI, Inc. $TEM

Y Intercept Hong Kong Ltd bought a new position in Tempus AI, Inc. (NASDAQ:TEM) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 132,418 shares of the company’s stock, valued at approximately $8,414,000. Y Intercept Hong Kong Ltd owned 0.08% of Tempus AI at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TEM. Concord Wealth Partners raised its stake in shares of Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after buying an additional 308 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Tempus AI in the first quarter worth about $33,000. Bartlett & CO. Wealth Management LLC raised its position in Tempus AI by 100.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock worth $39,000 after acquiring an additional 400 shares in the last quarter. Nemes Rush Group LLC bought a new stake in Tempus AI in the first quarter worth about $39,000. Finally, Quarry LP bought a new stake in Tempus AI in the first quarter worth about $44,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $89.23 on Monday. The company’s fifty day moving average is $84.20 and its two-hundred day moving average is $68.05. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $104.32. The company has a market cap of $15.50 billion, a P/E ratio of -74.98 and a beta of 4.87.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million for the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company’s revenue was up 89.5% on a year-over-year basis. During the same period in the previous year, the business earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Equities analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Eric P. Lefkofsky sold 332,500 shares of the company’s stock in a transaction dated Thursday, September 25th. The stock was sold at an average price of $76.56, for a total value of $25,456,200.00. Following the transaction, the chief executive officer owned 9,141,032 shares in the company, valued at $699,837,409.92. This represents a 3.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James William Rogers sold 7,528 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the transaction, the chief financial officer owned 138,473 shares in the company, valued at approximately $10,337,009.45. This represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold 767,412 shares of company stock valued at $57,618,856 in the last ninety days. Corporate insiders own 26.27% of the company’s stock.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of research reports. Morgan Stanley boosted their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Saturday. Piper Sandler upped their price target on Tempus AI from $70.00 to $105.00 and gave the company a “neutral” rating in a report on Wednesday. HC Wainwright boosted their target price on Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Canaccord Genuity Group assumed coverage on Tempus AI in a research report on Monday, October 20th. They set a “buy” rating and a $110.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus price target of $79.38.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.